文献速递脊柱关节炎

用于幼年轴性脊柱关节炎实用试验的反应性和区分性核心测量指标集

Core Set of Responsive and Discriminatory Measures for Use in Pragmatic Trials of Youth With Axial Juvenile Spondyloarthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-06-23

本研究为前瞻性多中心研究,纳入57例8-18岁接受TNFi治疗的幼年脊柱关节炎伴轴性疾病患者,在基线和12周评估反应性与区分性。最终核心集包含PROMIS疼痛干扰、骶髂关节炎症评分、PROMIS活动能力和患者总体健康状况。

要点

  • 最终axJSpA核心集含PROMIS疼痛干扰、骶髂关节炎症评分、PROMIS活动能力和患者总体健康状况。
  • 70.2%接受TNFi治疗的 youth 达到临床应答(患者总体评估变化≥2)。
  • 58%的患者仍有MRI炎症持续,但其中77%报告中度临床改善。

核心结论

  • 为幼年轴性脊柱关节炎(axJSpA)患者制定了一套核心测量指标集。

研究设计与样本

  • 前瞻性多中心研究,纳入57例8-18岁幼年脊柱关节炎伴轴性疾病患者,所有患者均启动肿瘤坏死因子抑制剂(TNFi)治疗,在基线和12周完成问卷、检查和磁共振成像(MRI)。

主要发现

  • 可评估队列57例中,68.4%为男性,中位年龄15.3岁;70.2%接受TNFi治疗的患者达到临床应答(患者总体评估变化≥2)。
  • 58%的患者仍有MRI炎症持续,但其中77%报告中度临床改善。
  • 最终axJSpA核心集包含:PROMIS疼痛干扰(SRM 0.77,SMD 0.5)、骶髂关节炎症评分(SRM 1.02,SMD 0.52)、PROMIS活动能力(SRM 0.83,SMD 0.75)和患者总体健康状况(SRM 0.88,SMD不适用)。
  • 所有测试的总体和复合疾病活动度指标中,除医生总体评估外,均具有高SRM和SMD。
  • 亚组分析显示生物学性别和超重状态存在差异:男性患者MRI炎症评分改善更大;体重指数正常者PROMIS疼痛干扰和活动能力改善更大。

关键数值与推荐

  • 最终axJSpA核心集包含PROMIS疼痛干扰(SRM 0.77,SMD 0.5)、骶髂关节炎症评分(SRM 1.02,SMD 0.52)、PROMIS活动能力(SRM 0.83,SMD 0.75)和患者总体健康状况(SRM 0.88,SMD不适用)。
  • 临床应答定义为患者总体评估变化≥2,70.2%接受TNFi治疗的患者达到该应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to determine a core set of measures for youth with juvenile spondyloarthritis and axial disease (axJSpA), using the juvenile arthritis working group Outcome Measures in Rheumatology framework. METHODS: This was a prospective multicenter study of youth with axJSpA. Participants (aged 8-18 years) all initiated tumor necrosis factor inhibitor (TNFi) therapy and completed questionnaires, examinations, and magnetic resonance imaging (MRI) at baseline and 12 weeks. Responsiveness and discrimination were assessed using standardized response mean (SRM) and standardized mean difference (SMD). For highly correlated (r > |0.80|) items within domains, larger SRM and SMD were prioritized, and minimal clinically important improvement was determined for each. RESULTS: Of the evaluable cohort (N = 57), 68.4% were male, and the median age was 15.3 years; 70.2% of youth treated with TNFi had clinical response (change ≥2 in patient global assessment). Although 58% had continued MRI inflammation, 77% of those patients reported moderate clinical improvement. The final axJSpA core set contained the following: Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference (SRM 0.77, SMD 0.5), the sacroiliac joint inflammation score (SRM 1.02, SMD 0.52), PROMIS mobility (SRM 0.83, SMD 0.75), and patient global well-being (SRM 0.88, SMD not applicable). All overall and composite disease activity measures tested, except the physician global assessment, had high SRM and SMD. Subgroup analysis demonstrated differences by biologic sex and overweight status. Improvement in the MRI inflammation score was greater in male patients. Improvement in the PROMIS pain interference and mobility measures was greater in those with normal body mass index. CONCLUSION: A set of measures was developed for youth with axJSpA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Brandon TG, Xiao R, Lovell DJ, et al. Core Set of Responsive and Discriminatory Measures for Use in Pragmatic Trials of Youth With Axial Juvenile Spondyloarthritis. Arthritis Care Res (Hoboken). 2025. PMID: 40317901. doi:10.1002/acr.25565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。